These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 34740923)

  • 1. Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score.
    Westphalen CB; Fine AD; André F; Ganesan S; Heinemann V; Rouleau E; Turnbull C; Garcia Palacios L; Lopez JA; Sokol ES; Mateo J
    Clin Cancer Res; 2022 Apr; 28(7):1412-1421. PubMed ID: 34740923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies.
    Zurita AJ; Graf RP; Villacampa G; Raskina K; Sokol E; Jin D; Antonarakis ES; Li G; Huang RSP; Casanova-Salas I; Vivancos A; Carles J; Ross JS; Schrock AB; Oxnard GR; Mateo J
    JCO Precis Oncol; 2022 Jul; 6():e2200195. PubMed ID: 35820087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway.
    Mahlow J; Barry M; Albertson DJ; Jo YJ; Balatico M; Seasor T; Gebrael G; Kumar SA; Sayegh N; Tripathi N; Agarwal N; Swami U; Sirohi D
    Hum Pathol; 2024 Feb; 144():28-33. PubMed ID: 38278448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-Cancer Analysis of
    Sokol ES; Pavlick D; Khiabanian H; Frampton GM; Ross JS; Gregg JP; Lara PN; Oesterreich S; Agarwal N; Necchi A; Miller VA; Alexander B; Ali SM; Ganesan S; Chung JH
    JCO Precis Oncol; 2020; 4():442-465. PubMed ID: 32903788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.
    Su Y; Yao Q; Xu Y; Yu C; Zhang J; Wang Q; Li J; Shi D; Yu B; Zeng Y; Zhu X; Bai Q; Zhou X
    Front Genet; 2021; 12():674094. PubMed ID: 34917121
    [No Abstract]   [Full Text] [Related]  

  • 6. RNA-Based Homologous Recombination Deficiency Signature Detects Homologous Recombination Deficiency-RNA+ Patients With and Without Homologous Recombination Repair Gene Pathogenic Alterations in Men With Prostate Cancer.
    Brown LC; Zhu J; Mauer E; Thiede SN; Macera L; Stein MM; Taxter T; Raghavan D; Burgess EF
    JCO Precis Oncol; 2023 Sep; 7():e2300378. PubMed ID: 38061006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.
    D'Angelo E; Espinosa I; Felicioni L; Buttitta F; Prat J
    Hum Pathol; 2023 Nov; 141():15-21. PubMed ID: 37673346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.
    Shao C; Wan J; Lam FC; Tang H; Marley AR; Song Y; Miller C; Brown M; Han J; Adeboyeje G
    Environ Mol Mutagen; 2022 Jul; 63(6):308-316. PubMed ID: 36054589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.
    Kim J; Jeong K; Jun H; Kim K; Bae JM; Song MG; Yi H; Park S; Woo GU; Lee DW; Kim TY; Lee KH; Im SA
    Hum Genomics; 2023 Jan; 17(1):2. PubMed ID: 36604691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic landscape of homologous recombination repair genes in early-onset/familial prostate cancer patients.
    Paulo P; Cardoso M; Brandão A; Pinto P; Falconi A; Pinheiro M; Cerveira N; Silva R; Santos C; Pinto C; Peixoto A; Maia S; Teixeira MR
    Genes Chromosomes Cancer; 2023 Dec; 62(12):710-720. PubMed ID: 37436117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
    Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA
    Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
    Kahn RM; Selenica P; Boerner T; Roche KL; Xiao Y; Sia TY; Maio A; Kemel Y; Sheehan M; Salo-Mullen E; Breen KE; Zhou Q; Iasonos A; Grisham RN; O'Cearbhaill RE; Chi DS; Berger MF; Kundra R; Schultz N; Ellenson LH; Stadler ZK; Offit K; Mandelker D; Aghajanian C; Zamarin D; Sabbatini P; Weigelt B; Liu YL
    Gynecol Oncol; 2024 Jan; 180():35-43. PubMed ID: 38041901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP Inhibitor Insensitivity to
    Sokol ES; Jin DX; Fine A; Trabucco SE; Maund S; Frampton G; Molinero L; Antonarakis ES
    JCO Precis Oncol; 2022 Jun; 6():e2100531. PubMed ID: 35772050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.
    Foretová L; Navrátilová M; Svoboda M; Vašíčková P; Sťahlová EH; Házová J; Kleiblová P; Kleibl Z; Macháčková E; Palácová M; Petráková K
    Klin Onkol; 2019; 32(Supplementum2):6-13. PubMed ID: 31409076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study.
    Chen C; Dettman EJ; Zhou W; Gozman A; Jin F; Lee LC; Ren Y; Zhou H; Cristescu R; Shao C
    Future Oncol; 2024 Jul; ():1-14. PubMed ID: 39011875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors.
    Chung JH; Dewal N; Sokol E; Mathew P; Whitehead R; Millis SZ; Frampton GM; Bratslavsky G; Pal SK; Lee RJ; Necchi A; Gregg JP; Lara P; Antonarakis ES; Miller VA; Ross JS; Ali SM; Agarwal N
    JCO Precis Oncol; 2019; 3():. PubMed ID: 31218271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
    Takamatsu S; Brown JB; Yamaguchi K; Hamanishi J; Yamanoi K; Takaya H; Kaneyasu T; Mori S; Mandai M; Matsumura N
    JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34423229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of Tumor Genomic Alterations in Homologous Recombination Repair Genes Among Taiwanese Breast Cancers.
    Huang CC; Tsai YF; Liu CY; Lien PJ; Lin YS; Chao TC; Feng CJ; Chen YJ; Lai JI; Phan NN; Hsu CY; Chiu JH; Tseng LM
    Ann Surg Oncol; 2022 Jun; 29(6):3578-3590. PubMed ID: 35226219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response.
    Moore JA; Chen KT; Madison R; Newberg JY; Fleischmann Z; Wang S; Sharaf R; Murugesan K; Fendler BJ; Hughes J; Schrock AB; Hegde PS; Oxnard GR; Fabrizio D; Frampton GM; Antonarakis ES; Sokol ES; Jin DX
    JCO Precis Oncol; 2023 Sep; 7():e2300093. PubMed ID: 37769224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
    de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
    Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.